The maladaptive effects of HIV protease inhibitors (lopinavir/ritonavir) on the rat heart

被引：9
|
作者：
Reyskens, Kathleen M. S. E. [1 ]
Essop, M. Faadiel [1 ]
机构：
[1] Univ Stellenbosch, CMRG, Dept Physiol Sci, ZA-7600 Stellenbosch, South Africa
来源：
INTERNATIONAL JOURNAL OF CARDIOLOGY | 2013年 / 168卷 / 03期
基金：
新加坡国家研究基金会;
关键词：
HIV-AIDS; HIV protease inhibitors; Cardiovascular diseases; Ischemia-reperfusion; Metabolism;
D O I：
10.1016/j.ijcard.2013.04.128
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
[No abstract available]
引用
收藏
页码：3047 / 3049
页数：4
相关论文
共 50 条
  • [41] Influence of Baseline Protease Inhibitor Resistance on the Efficacy of Darunavir/Ritonavir or Lopinavir/Ritonavir in the TITAN Trial
    De Meyer, Sandra
    Hill, Andrew
    Picchio, Gaston
    DeMasi, Ralph
    De Paepe, Els
    de Bethune, Marie-Pierre
    JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2008, 49 (05) : 563 - 564
  • [42] Resistance to amprenavir before and after treatment with lopinavir/ritonavir in highly protease inhibitor-experienced HIV patients
    Hasson, H
    Gianotti, N
    Danise, A
    Seminari, E
    Boeri, E
    Nozza, S
    Castagna, A
    Lazzarin, A
    AIDS, 2004, 18 (01) : 123 - 127
  • [43] The protease inhibitor combination lopinavir/ritonavir does not decrease insulin secretion in healthy, HIV-seronegative volunteers
    Pao, V. Y.
    Lee, G. A.
    Taylor, S.
    Aweeka, F. T.
    Schwarz, J-M
    Mulligan, K.
    Schambelan, M.
    Grunfeld, C.
    ANTIVIRAL THERAPY, 2009, 14 (07) : A39 - A40
  • [44] The protease inhibitor combination lopinavir/ritonavir does not decrease insulin secretion in healthy, HIV-seronegative volunteers
    Pao, Vivian Y.
    Lee, Grace A.
    Taylor, Steven
    Aweeka, Francesca T.
    Schwarz, Jean-Marc
    Mulligan, Kathleen
    Schambelan, Morris
    Grunfeld, Carl
    AIDS, 2010, 24 (02) : 265 - 270
  • [45] Emergence of protease resistance during simplification therapy with lopinavir/ritonavir alone
    Sprinz, Eduardo
    Jeffman, Marcelo
    HIV CLINICAL TRIALS, 2007, 8 (02): : 105 - 106
  • [46] Clearance and clearance inhibition of the HIV-1 protease inhibitors ritonavir and saquinavir in sandwich-cultured rat hepatocytes and rat microsomes
    Treijtel, N.
    van Eijkeren, J. C. H.
    Nijmeijer, S.
    de Greef-van der Sandt, I. C. J.
    Freidig, A. P.
    TOXICOLOGY IN VITRO, 2009, 23 (01) : 185 - 193
  • [47] Cost effectiveness of lopinavir/ritonavir compared with atazanavir in antiretroviral-naive patients - Modelling the combined effects of HIV and heart disease
    Simpson, Kit N.
    Luo, Michelle P.
    Chumney, Elinor C.
    King, Martin S.
    Brun, Scott
    CLINICAL DRUG INVESTIGATION, 2007, 27 (01) : 67 - 74
  • [48] Therapeutic drug monitoring of Indinavir and lopinavir boosted with ritonavir in children with HIV-1 infection:: Possible influence of P-gp on protease inhibitors absorption
    Bramuglia, Guillermo F.
    Curras, Veronica
    Hocht, Christian
    Mangano, Andrea
    Niselman, Viviana
    Guido, Paulo Caceres
    Mecikovsky, Debora
    Bellusci, Carolina
    Bologna, Rosa
    Sen, Luisa
    Rubio, Modesto C.
    THERAPEUTIC DRUG MONITORING, 2007, 29 (04) : 487 - 487
  • [49] Effects of atazanavir/ritonavir and lopinavir/ritonavir on glucose uptake and insulin sensitivity
    Caumo, Andrea
    Guffanti, Monica
    Perseghin, Gianiuca
    Galli, Laura
    Lazzarin, Adriano
    Luzi, Livio
    Castagna, Antonella
    AIDS, 2007, 21 (17) : 2366 - 2367
  • [50] Profound drug interaction with a combination of two protease inhibitors (PI: ritonavir and lopinavir: Kaletra®) and tacrolimus in post-liver transplant (LTx) patients with HIV infection
    Jain, AB
    Venkataramanan, R
    Eghtesad, B
    Marcos, A
    Ragni, M
    Shapiro, R
    Rafail, A
    Fung, JJ
    LIVER TRANSPLANTATION, 2003, 9 (06) : C81 - C81
12345